Network origin in Thomas R. Parr first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 24 | |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.
4
| Extinct | Pharmaceuticals: Major | 4 |
Xenogen Corp.
 Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA.
1
| Subsidiary | Medical Specialties | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Thomas R. Parr via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BIOGEN INC. | Pharmaceuticals: Major | Sales & Marketing | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | General Counsel Chief Operating Officer General Counsel | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Micreos BV
 Micreos BV Pharmaceuticals: GenericHealth Technology Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands. | Pharmaceuticals: Generic | Chairman | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
Morrison & Foerster LLP
 Morrison & Foerster LLP Miscellaneous Commercial ServicesCommercial Services Morrison & Foerster LLP is a law firm that provides legal services on various industries, which include: litigation, financial services, intellectual property and technology, and transactional work, such as corporate, capital markets and real estate finance representations. The company was founded in 1883 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Rice University | College/University | Undergraduate Degree Undergraduate Degree | |
| MACROGENICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
Philabundance
 Philabundance Services to the Health IndustryHealth Services Philabundance provides food services to the community. The company was founded in 1984 by Pamela Rainey Lawler and is headquartered in Philadelphia, PA. | Services to the Health Industry | Director/Board Member | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| GLYCOMIMETICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| NEXSTIM PLC | Medical Specialties | Director/Board Member | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
DYSIS Medical Ltd.
 DYSIS Medical Ltd. Medical SpecialtiesHealth Technology DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom. | Medical Specialties | Director/Board Member Director/Board Member | |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Niels Clauson-Kaas A/S
 Niels Clauson-Kaas A/S Miscellaneous Commercial ServicesCommercial Services Niels Clauson-Kaas A/S provides research and experimental development services in the fields of natural sciences and engineering. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
BiognoSYS AG
 BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Chairman | |
Athyrium Capital Management LP
 Athyrium Capital Management LP Investment ManagersFinance Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors. | Investment Managers | Consultant / Advisor | |
| ARCH BIOPARTNERS INC. | Pharmaceuticals: Major | Director/Board Member | |
Lundbeckfonden Ventures
 Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Investment Managers | Consultant / Advisor Private Equity Investor | |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Biotechnology | Compliance Officer Human Resources Officer | |
| INHIBIKASE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| CIRCIO HOLDING ASA | Biotechnology | Chairman | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| ADVANZ PHARMA CORP. LIMITED | Pharmaceuticals: Major | Director/Board Member | |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Chairman | |
| ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Chairman | |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Director/Board Member | |
Essential Pharmaceuticals LLC
 Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a private company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017. | Pharmaceuticals: Major | Chairman | |
Essential Pharmaceuticals Ltd.
 Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
| Gyrus Capital SA | Investment Managers | Private Equity Investor | |
| AMRYT PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
| F2g Inc. | Director/Board Member |
Statistics
International
| United States | 24 |
| United Kingdom | 9 |
| Denmark | 7 |
| Switzerland | 5 |
| Netherlands | 4 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 6 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 2 |
Operational
| Director/Board Member | 131 |
| Corporate Officer/Principal | 65 |
| Independent Dir/Board Member | 35 |
| Director of Finance/CFO | 34 |
| Undergraduate Degree | 21 |
Most connected contacts
| Insiders | |
|---|---|
| Jean-Francois Formela | 47 |
| Patrick Volkert Vink | 30 |
| Stephen DiPalma | 24 |
| David Southwell | 19 |
| Tamara Joseph | 19 |
| William Halter | 19 |
| Casper Breum | 18 |
| Vikas Goyal | 16 |
| Scott Jackson | 15 |
| Frank Thomas | 14 |
| Cynthia Smith | 13 |
| Joel D. Sendek | 11 |
| John Pottage | 10 |
| Williamson Z. Bradford | 10 |
| Jay Blackington | 8 |
- Stock Market
- Insiders
- Thomas R. Parr
- Company connections